405results about How to "Good clinical value" patented technology

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.

The invention relates to a DTI (Diffusion Tensor Imaging)-based cranial nerve fiber bundle three-dimensional rebuilding method and a method of manufacturing a head three-dimensional model comprising nerve fiber bundles based on a 3D printing technology. The method comprises the following steps: magnetic resonance scanning is carried out on a target tissue area and surrounding nerve fiber bundles to acquire MRI image data for the target tissue area comprising the nerve fiber bundles; DTI processing and related processing are carried out on the acquired MRI image to acquire an MRI image with an identifiable nerve fiber bundle; calculation is carried out on X-axis information, Y-axis information and Z-axis information of the MRI image with the identifiable nerve fiber bundle, three-dimensional rebuilding is carried out via mimics software, and a three-dimensional mode comprising the cranial nerve fiber bundle is acquired. Through the three-dimensional model and the 3D printing three-dimensional solid model, the position relation among an anatomic structure, a brain function area and each tissue can be displayed clearly, a solid model is provided for an operation, and the method is used for operation approach design and operation simulation.

The invention relates to a photosensitive PRP (platelet-rich plasma) gel and a preparation method and application thereof. The preparation method comprises the following steps of mixing a biocompatible medium solution of a macromolecule modified by an o-nitrobenzyl photo response group and an extracted PRP according to a certain ratio, so as to form a gel precursor solution; then, radiating the gel precursor solution by light, and enabling the o-nitrobenzyl group in the macromolecule modified by the o-nitrobenzyl photo response group to generate photochemical reaction under the excitation action of a light source, so as to produce an aldehyde functional group; generating coupling reaction with amino distributed at the surface of the protein in the PRP to form an imine bond, so as to realize the preparation of the photosensitive PRP gel. Compared with the prior art, the photosensitive PRP gel prepared by the method has the advantages that the internal cell factors can be slowly released, and the tight and seamless bonding between the PRP gel and wounds is realized.

The invention provides a glomerulus-targeted protein nanoparticle pharmaceutical composition and an application thereof. The protein nanoparticle pharmaceutical composition is mainly prepared from a protein ingredient, a pharmacological active substance and a stabilizer, and the grain size of the protein nanoparticle pharmaceutical composition ranges from 10nm to 170nm. With the application of the pharmaceutical composition, passive targeted drug delivery of glomerular mesangial cells is achieved, and the aggregation concentration of a drug in a glomerulus is obviously improved or the aggregation duration of the drug in the glomerulus is prolonged, so that the curative effect of the drug is remarkably improved, and meanwhile, the toxic and side effects of the drug on a non-targeted part are greatly reduced.

The invention discloses a hepatocellular carcinoma automatic grading method based on an SE-DenseNet deep learning framework and an enhanced MR image. The method comprises the following steps of 1) collecting data; 2) preprocessing all hepatocellular carcinoma three-dimensional images with enhanced MR; 3) enhancing the training data; 4) based on the enhanced training data, training a hepatocellularcarcinoma grading prediction model, namely an SE-DenseNet network; and 5) carrying out hierarchical prediction on the test data by adopting the trained model, and evaluating the classification performance of the hepatocellular carcinoma hierarchical prediction model. According to the automatic pathological grading method for the hepatocellular carcinoma multi-modal enhanced MR image which is composed of the steps of image preprocessing, the image enhancement, the hepatocellular carcinoma multi-modal enhanced MR image classification, SE-DenseNet network training and SE-DenseNet network testing, the hepatocellular carcinoma automatic grading can be realized, and the problems of manpower consumption, time consumption and subjective difference existing in manual hepatocellular carcinoma grading can be solved.

A nanopartide and its avidin probe are disclosed. Said gene probe for detecting the mutation or non-mutation of DNA is prepared from nanoparticles or colloidal particles and avidin, streptavidin, or antibiotin through preparing colloidal gold and preparing the compound. Its advantges are high sensitivity, specificity and speed.

The invention provides a hepatic carcinoma targeted photo-thermal therapeutic agent as well as a preparation method and an application thereof and belongs to the field of biomedical engineering. The hepatic carcinoma targeted photo-thermal therapeutic agent is prepared with the method comprising the following steps: (1) preparing biotinylation nanometer microbubbles; (2) preparing a Cy7 fluorescently-labeled biotinylation anti-GPC3 (glypican3) antibody; (3) preparing biotinylation RGO (reduced graphene oxide); (4) coupling the products prepared in the step (1), step (2) and step (3) through a biotin-avidin system to obtain the hepatic carcinoma targeted photo-thermal therapeutic agent. The hepatic carcinoma targeted photo-thermal therapeutic agent has ultrasonic and fluorescence imaging functions, mediates RGO targeted delivery with an ultrasound-targeted microbubble destruction technology, monitors a photo-thermal therapeutic process in real time, can be used for preparing drugs for hepatic carcinoma therapy and has excellent clinical application value.

The invention relates to a preparation method and application of a reduction-response-type pegylation (PEG) nanomedicine composition. The nanomedicine composition is characterized by being prepared by coupling the PEG with a medicine via disulfide bonds which are sensitive in reduction. Thus, the water solubility of the medicine is improved; the in-vivo behavior of the medicine is also improved. Meanwhile, the full release and the activity of the medicine are ensured by utilizing the characteristic that the disulfide bonds in the PEG medicine, which are sensitive in reduction, can be specifically degraded in a tumor site. Thus, a good tumor treatment scheme is provided.

The invention discloses a biodegradable magnetic nano gold shell microsphere as well as a preparation method and application thereof. The nano gold shell microsphere has a core-shell structure, wherein the inner core is a gelatin magnetic ferroferric oxide microsphere, and the core layer is a gold nano shell; and the diameter of the nano gold shell microsphere is 55-1000 nanometers, the diameter of the inner core is 50-800 nanometers, and the thickness of the shell layer is 5-200 nanometers. The microsphere prepared by the method disclosed by the invention is good in magnetism, narrow in particle size distribution and controllable in outer shell thickness and particle size. Because gelatin is a good in vivo biodegradable material, along with the degradation of the magnetic inner core, the outside nano gold shell layer is disintegrated into gold nano particles and is discharged out of a body at last. The preparation method is simple and convenient in process, simple to operate, low in cost and easy for large-scale production. Meanwhile, the biodegradable magnetic nano gold shell microsphere has functions of magnetic resonance targeted imaging and photo-thermal treatment, and more importantly, the biodegradability of the microsphere greatly reduces the toxic or side effects of the gold shell on human bodies, so that the biodegradable magnetic nano gold shell microsphere has a very good clinical application value.

The invention belongs to the field of medical apparatuses and instruments, and in particular discloses a gait rehabilitation robot and a method for controlling the gait rehabilitation robot. The method comprises the following steps: according to a wearable sensor system, measuring a two-dimensional lower limb posture of a user in real time during walking, calculating the walking speed of the user, and controlling the operating speed of the robot according to the walking speed. The method is convenient to use and low in cost and is not limited by the site, and the gait rehabilitation robot can well follow the walking speed and gait characteristics of the user, so that the aim of helping the user to walk is achieved, secondary injury to the user can be avoided, and the gait rehabilitation robot has high reliability and excellent popularization prospects.

The invention provides an miRNA marker associated with genomic stability of human umbilical cord blood mesenchymal stem cells and a detection method of the miRNA marker. A new generation of high-throughput sequencing technology is used, in combination with a bioinformatic analysis method of a system, to screen and obtain the miRNA associated with genomic stability of human umbilical cord blood mesenchymal stem cells, wherein an RNA sequence is shown in SEQ IDNO.1-5. The invention also provides a specific primer for detecting the miRNA and a detection method of the specific primer, wherein conditions for the detection method of human umbilical cord blood mesenchymal stem cells are optimized. Through the detection of the specific miRNA marker provided by the invention, the genomic stability of human umbilical cord blood-derived mesenchymal stem cells after passage or amplification can be estimated effectively, to reduce costs and the risk of subsequent clinical application; the miRNA has excellent clinical application value and broad application prospect.

The invention relates to a preparation method of a tissue model with a cavity structure and the issue model. The method comprises the following steps: as for a target tissue with a cavity structure, acquiring a first three-dimensional geometric model having the same contour shape and size with a tissue; shrinking the first three-dimensional geometric model in the radial direction according to the wall thickness of the tissue, so as to obtain a second three-dimensional geometric model; manufacturing a bracket according to the second three-dimensional geometric model; coating a material used for manufacturing the tissue model on the surface of the bracket according to the wall thickness of the tissue; removing the bracket after the material is solidified, and obtaining the tissue model with the cavity structure. The high-precision tissue model, of which the size is close to that of the real tissue, is obtained for the tissue with the cavity structure through size design; as the tissue model is obtained through coating, the material of the tissue model is not limited by a consumable item of a traditional 3D printer, and the purpose of preparing the tissue model by choosing any proper material is fulfilled.

The present invention provides a method for predicting the risk of occurrence of cancer. It also predicts the presence of BRCA mutations which in turn predicts the risk of developing breast cancer in women. Further, it assesses a cancer patient's level of sensitivity to chemotherapy.

The invention relates to the technical field of biological detection, in particular to application of an amino acid molecular combination as a stomach cancer marker. The invention discloses application of an amino acid molecular combination as a stomach cancer marker in preparation of stomach cancer detection kits. The amino acid molecular combination is composed of alanine, glycine, valine, serine, threonine, proline, methionine and tyrosine. As a stomach cancer marker, the amino acid combination provided by the invention has the characteristics of very good sensitivity and specificity, simple operation and little time. At the same time, the detection sample adopted by the invention is urine, thus avoiding physical pain brought to patients due to use of tissue and blood samples. Therefore, no matter from patient compliance or from the accuracy of detection results, the amino acid combination provided by the invention as the stomach cancer marker, especially an early stomach cancer marker has very good clinical application value.

The invention provides a miRNA (micro Ribonucleic Acid) marker and a kit related to postmenopausal osteoporosis and particularly relates to application of a miR-338 cluster as a postmenopausal osteoporosis marker. According to the invention, high expression of the miR-338 cluster such as miR-338-3p and / or miR-3065-5p in postmenopausal osteoporosis patients is found; the miR-338 cluster can be used as a marker for the postmenopausal osteoporosis and is used for preparing an auxiliary diagnosis kit for the postmenopausal osteoporosis; the auxiliary diagnosis kit can be used for specifically detecting the expression quantity of the miR-338 cluster in tissues and is early and effectively used for early auxiliary diagnosis of clinical postmenopausal osteoporosis without noninvasive. Besides, an inhibitor of the miR-338 cluster has the efficacy of promoting osteogenesis, so that the postmenopausal osteoporosis is effectively treated or prevented.

The invention discloses a preparation method for a drug-loadable tissue repairing membrane. The drug-loadable tissue repairing membrane comprises an electrospun fibrous membrane main body, at least one hermetic drug storage chamber formed in the electrospun fibrous membrane main body and a drug storage medium arranged in the drug storage chamber, wherein the electrospun fibrous membrane main body is prepared from a hydrophobic degradable material, and the drug storage medium is prepared from a hydrophilic degradable material. According to the tissue repairing membrane in the invention, the drug storage medium is wrapped in the electrospun fibrous membrane main body, and a drug solution can be injected into the drug storage medium before usage of the tissue repairing membrane so as to realize the drug loading and sustained drug releasing functions of the tissue repairing membrane, so the tissue repairing membrane is simple and convenient to use and prevents destroy of factors like organic solvents in conventional drug loading methods to drugs; moreover, the tissue repairing membrane can realize in-situ long-term stable drug delivery during tissue repairing, does not need to take out, is simple to operate and has good clinical application value in the field of tissue repairing.

A SARS-Cov gene vaccine based on epitope is configured from the carrier which is a plasmid able to be used for human body and the target antigen which is several B cell epitopes in the extrinsic B protein antigen of human SARS coronavirus through codon optimizing and genetic engineering. Its preparing process is also disclosed.

The invention relates to a method for separating and culturing human adipose-derived stem cells. The method comprises the following steps: (1) digesting an adipose suction substance by adopting a mixed digestive enzyme solution which consists of collagenase I, collagenase II and ACCUTASE, neutralizing the digestive enzyme after digesting is ended, centrifuging, filtering, and then further removinghybrid cells by using a lymphocyte separating liquid; (2) culturing adipose-derived stem cells by adopting a serum-free culture medium. According to the method for separating and culturing the humanadipose-derived stem cells, on one hand, cells can be dissociated from an adipose tissue quickly and effectively, the yield of the stem cells is improved, the cell separating time is shortened, and the activity of the cells is kept to the greatest extent; on the other hand, the culture medium is clear in components, does not contain any exogenous serum component, can remarkably improve the wall adhering capacity and the multiplication capacity of the adipose-derived stem cells, is beneficial to in-vitro amplification and stemness maintenance of the adipose-derived stem cells, and has a good application prospect.

The invention discloses polysaccharide biomedical colloid. The colloidal fluid is prepared from, by weight, 0.5-10% of sodium carboxymethyl cellulose, 0.5-1.5% of sodium chloride, 0.5-1.5% of carbomer, 0.08-0.7% of sodium hyaluronate, 0.01-0.05% of phytate, 0.02-0.1% of sodium alginate, 0.1-0.3% of glycerol, 0.15-0.45% of chitobiose, 0.15-0.35% of polyhexamethylene guanidine, 0.01-0.2% of liquorices extract and the balance water used for injection. By means of formula optimization, the polysaccharide biomedical colloid is free of toxic and side effects, has great clinical application value, is short in healing time and high in healing rate, forms a wound surface wet environment, can directly restrain scar forming when used for cell repairing, and can form a wound surface protection film, block injuries caused by bacteria to wound surfaces, and restrain the adsorption process, the multiplication process, the copying process and other processes of bacteria on wound surfaces.

The invention discloses a cis-dammine dichloroplatinum (CDDP) prodrug, a preparation method and application. The structural formula of the CDDP prodrug is shown as formula (I), and is generated by theesterification reaction of activated dihydroxy cisplatin with hydrophobic molecules. Characterization of the nano-preparation by dynamic light scattering and transmission electron microscopy indicates that the nanoparticles involved in the invention are uniformly distributed and are at about 30nm. In vitro cytotoxicity experiments show that the nano-drug can significantly inhibit the proliferation of tumor cells (A549 and LoVo). In vivo experiments show that compared with CDDP injections, on the basis of reducing the systemic toxicity, the nano-drug has the effect of inhibiting the non-smallcell lung cancer A549 subcutaneous tumor, and has good market prospects and clinical application value.

The invention discloses a double labelling Nano-Au probe and a preparation method and application thereof. The probe comprises a Nano-Au particle as a core, the surface of which is connected with antibody and oligonucleotide simultaneously. The preparation method of the double labelling Nano-Au probe includes the following steps: (1) coupled reaction: adding oligonucleotide solution and antibody solution in Nano-Au sol with certain concentration and uniformly mixing the solutions to lead the Nano-Au particle, the antibody and nucleic acid to fully act in the solution; and (2) stabilizing and blocking reaction: preparing PBS buffer solution with the content of SDS being 5-10 percent and then adding the PBS buffer solution in the mixed solution prepared in step (1) and adding sealant to form nano probe sol. The double labelling Nano-Au probe can convert the antigenic detection into the detection of nucleic acid matter and is applied to the detection of tumor marker, hormone and pathogene micro-protein.

The invention relates to a serum exosome miRNA biological marker and a kit for early diagnosis of gastric cancer. The serum exosome miRNA biological marker consists of miR-19b and miR-106a. The serum exosome miRNA biological marker uses serum exosomes miRNA, especially two miRNA (hsa-MiR-19b-3p united hsa-miR-106a-5p) closely relevant with a gastric cancer serve as gastric-cancer early diagnosis markers, and the marker is superior to clinic means such as an existing gastroscope in early diagnosis and has better specificity and sensitivity. The kit consists of a specific amplification primer and a general PCR amplification reagent, has a good clinical application value in early diagnosis of the gastric cancer and provides a new thinking and method for improvement of the early diagnosis level of the gastric cancer.

The invention relates to a functionalized dendrimer-based SPECT-CT bimodal imaging contrast agent and a preparation method thereof. The functionalized dendrimer-based SPECT-CT bimodal imaging contrast agent is obtained by pegylation modified fifth polyamide-amine dendrimer as a polymer carrier material; connecting diethylenetriaminepentaacetic acid on the dendrimer surface through covalent grafting; coating gold nanoparticles through an in-situ synthesis method; carrying out acetylation or hydroxylation on residual surface amino groups; and marking <99m>Tc. The functionalized dendrimer-based SPECT-CT bimodal imaging contrast agent has a very good SPECT / CT imaging effect, realizes SPECT / CT imaging of different in-vivo tissue sites of a mouse, lays good foundation for development of multi-functional tissue specific contrast agent, and has wide application prospects.

The present invention relates to a Chinese medicine tupistra chinensis extract, its preparation method and application. Said extract is obtained by extracting root, stem and leaf of tupistra chinensis, and is a brownish yellow powder. The characteristics of its chemical identification are as follows: Liebermann-Burchard reaction and Molish reaction are positive; the foam test is positive reaction, the foam height of alkaline liquor tube is higher than that of acid liquor tube; Rosen-Heimer reaction at 60deg.C can produce violet red color reaction, it is a steroid saponin compound. Said extract has the action of resisting tumor, resisting inflammation, inhibiting platelet agglutination and resisting thrombosis.

The invention relates to a diagnosis primer and kit for type 2 diabetes, and an application of a non-coding RNA molecular marker. The diagnosis primer comprises a miR-802 forward primer as shown in SEQ ID NO:3 and a miR-802 reverse primer as shown in SEQ ID NO:4; the diagnosis kit for type 2 diabetes comprises the diagnosis primer; the non-coding RNA molecular marker is has-miR-802, or has-miR-802and has-lncRNA-ROIT; and the above diagnosis primer and non-coding RNA molecular marker can diagnose diabetes. The present invention can diagnose type 2 diabetes by utilizing the diagnosis primer / thediagnosis kit and by detecting the non-coding RNA molecular marker. The detection method is simple to operate, high in sensitivity and high in specificity, has small trauma to a subject, can be usedfor diagnosing type 2 diabetes in early stage and different stages, and has obvious clinical application value.

The invention provides a novel crystal form of ibrutinib. The novel crystal form is named as a crystal form 1; the 2-theta value of the X-ray powder diffraction pattern of the novel crystal form has characteristic peaks at 5.8 degrees + / - 0.2 degree, 10.8 degrees + / - 0.2 degree, 19.2 degrees + / - 0.2 degree, and 21.6 degrees + / - 0.2 degree; the novel crystal form has a heat absorption peak when being heated to about 150.3 DEG C; the novel crystal form is an anhydrous substance and is non-hygroscopic. The crystal form I of ibrutinib provided by the invention is good in solubleness, beneficial to improvement of oral bioavailability of medicines and relatively good in clinical application values. The crystal form I of ibrutinib is good in stability and almost has no hygroscopicity, so that stability of the medicines in the storage and transportation process and the safety in clinical application are ensured. The crystal form I of ibrutinib provided by the invention is simple in preparation method operation, low in cost, free of special requirement on production equipment, easy in industrial production and relatively great in application value.

The invention provides lung adenocarcinoma exosome specific miRNAs, and a target gene and applications thereof. High flux sequencing technology is combined with systematic bioinformatics analysis methods, the specific high-content exosome miRNAs related with lung adenocarcinoma is obtained through screening; the RNA sequences of the lung adenocarcinoma exosome specific miRNAs are represented by SEQ ID No.1-3. It is found that the common target gene of the miRNAs is FOXN3. The target gene is capable of inhibiting fibroblast migration capability, reduction of the expression amount of the targetgene is capable of promoting entering of fibroblast into tumor tissues, and promoting tumor growth. The lung adenocarcinoma exosome specific miRNAs and the target gene thereof can be taken as lung adenocarcinoma diagnosis markers and can be used for preparation of diagnostic kits. An inhibitor of the miRNAs or an expression promoter of the target gene can be used for preparing medicines used for treating lung adenocarcinoma, or medication guidance in treatment of lung adenocarcinoma; and the clinical application value is relatively high, and the application prospect is promising.

The invention relates to a preparation method of purified and amplified human mesenchymal stem cells. The method comprises the following steps: (1) collecting mesenchymal stem cells by adopting an antibody-based negative sorting method; and (2) amplifying the mesenchymal stem cells by adopting a serum-free culture medium. The preparation method is superior to a conventional separation method, and the serum-free culture medium provided by the method is remarkably better than a conventional serum culture medium in the fields of safety and amplifying capability and has excellent application prospect.

The invention discloses a non-natural amino acid modified endomorphin-1 analogue. A synthesis method comprises the following step: replacing amino acid phenylalanine at a fourth site from a terminal N to a terminal C of parent endomorphin-1 by respectively using 2-thienyl substituted alpha-alkenyl-beta-amino acid and 3-thienyl substituted alpha-alkenyl-beta-amino acid. The affinity and enzymatic hydrolysis stability of a mu opioid receptor of the non-natural amino acid modified endomorphin-1 analogue can be effectively improved, and thus the in-vivo analgesic effect of the non-natural amino acid modified endomorphin-1 analogue can be further improved and prolonged; and the non-natural amino acid modified endomorphin-1 analogue is subjected to pharmacological activity identification by virtue of radioligand receptor binding experiments, in-vitro organ biological assays and in-vitro enzymatic hydrolysis stability and warm bath tail-flick analgesic experiments, and results show that compared with parent endomorphin-1, the synthesized non-natural amino acid modified endomorphin-1 analogue disclosed by the invention has higher affinity, higher enzymatic hydrolysis stability and higher analgesic activity, and has potential application values of being taken as clinical polypeptide analgesic medicines.

The invention discloses a zirconium dioxide composite nanometer material with microwave sensitization, chemotherapy dry release and CT imaging functions and a preparation method and application thereof. The zirconium dioxide composite nanometer material comprises a hollow zirconium dioxide nanometer material and trametes polysaccharide. The hollow part of the zirconium dioxide nanometer material of the zirconium dioxide composite nanometer material is filled with the trametes polysaccharide. The grain size of the zirconium dioxide composite nanometer material is 50-500 nm; the thickness of a shell is 10-100 nm. The prepared zirconium dioxide composite nanometer material is good in dispersity; the size and thickness of the shell can be adjusted as needed. The hollow part of the zirconium dioxide is filled with the traditional Chinese medicine trametes polysaccharide with the chemotherapy effect for the first time; the zirconium dioxide composite nanometer material can be applied to the technical fields of microwave sensitization, chemotherapy dry release and CT imaging at the same time, achieves the target of treating the tumor through the diagnosis and treatment integration and targeted hyperthermia chemotherapy and has good clinical application prospects.